These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

699 related articles for article (PubMed ID: 25690937)

  • 1. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
    Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
    Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological and clinical significance of PARP1 protein expression in breast cancer.
    Green AR; Caracappa D; Benhasouna AA; Alshareeda A; Nolan CC; Macmillan RD; Madhusudan S; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2015 Jan; 149(2):353-62. PubMed ID: 25528020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response protein.
    Alshareeda AT; Negm OH; Aleskandarany MA; Green AR; Nolan C; TigHhe PJ; Madhusudan S; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2016 Aug; 159(1):41-53. PubMed ID: 27464795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological significance of KU70/KU80, a key DNA damage repair protein in breast cancer.
    Alshareeda AT; Negm OH; Albarakati N; Green AR; Nolan C; Sultana R; Madhusudan S; Benhasouna A; Tighe P; Ellis IO; Rakha EA
    Breast Cancer Res Treat; 2013 Jun; 139(2):301-10. PubMed ID: 23624778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
    Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
    Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
    Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
    Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA signatures in hereditary breast cancer.
    Murria Estal R; Palanca Suela S; de Juan Jiménez I; Egoavil Rojas C; García-Casado Z; Juan Fita MJ; Sánchez Heras AB; Segura Huerta A; Chirivella González I; Sánchez-Izquierdo D; Llop García M; Barragán González E; Bolufer Gilabert P
    Breast Cancer Res Treat; 2013 Nov; 142(1):19-30. PubMed ID: 24129975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
    Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF
    BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic exploitation of tumor cell defects in homologous recombination.
    Powell SN; Kachnic LA
    Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1 promoter hypermethylation, 53BP1 protein expression and PARP-1 activity as biomarkers of DNA repair deficit in breast cancer.
    Jacot W; Thezenas S; Senal R; Viglianti C; Laberenne AC; Lopez-Crapez E; Bibeau F; Bleuse JP; Romieu G; Lamy PJ
    BMC Cancer; 2013 Nov; 13():523. PubMed ID: 24191908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors.
    Honrado E; Osorio A; Palacios J; Milne RL; Sánchez L; Díez O; Cazorla A; Syrjakoski K; Huntsman D; Heikkilä P; Lerma E; Kallioniemi A; Rivas C; Foulkes WD; Nevanlinna H; Benítez J
    J Clin Oncol; 2005 Oct; 23(30):7503-11. PubMed ID: 16234517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.
    Eerola H; Heinonen M; Heikkilä P; Kilpivaara O; Tamminen A; Aittomäki K; Blomqvist C; Ristimäki A; Nevanlinna H
    Breast Cancer Res; 2008; 10(1):R17. PubMed ID: 18275599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The DNA damage signalling kinase ATM is aberrantly reduced or lost in BRCA1/BRCA2-deficient and ER/PR/ERBB2-triple-negative breast cancer.
    Tommiska J; Bartkova J; Heinonen M; Hautala L; Kilpivaara O; Eerola H; Aittomäki K; Hofstetter B; Lukas J; von Smitten K; Blomqvist C; Ristimäki A; Heikkilä P; Bartek J; Nevanlinna H
    Oncogene; 2008 Apr; 27(17):2501-6. PubMed ID: 17982490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased ID4 expression, accompanied by mutant p53 accumulation and loss of BRCA1/2 proteins in triple-negative breast cancer, adversely affects survival.
    Thike AA; Tan PH; Ikeda M; Iqbal J
    Histopathology; 2016 Apr; 68(5):702-12. PubMed ID: 26259780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and BRCA2 protect against oxidative DNA damage converted into double-strand breaks during DNA replication.
    Fridlich R; Annamalai D; Roy R; Bernheim G; Powell SN
    DNA Repair (Amst); 2015 Jun; 30():11-20. PubMed ID: 25836596
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
    Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
    [No Abstract]   [Full Text] [Related]  

  • 17. Glycodelin expression associates with differential tumour phenotype and outcome in sporadic and familial non-BRCA1/2 breast cancer patients.
    Hautala LC; Greco D; Koistinen R; Heikkinen T; Heikkilä P; Aittomäki K; Blomqvist C; Koistinen H; Nevanlinna H
    Breast Cancer Res Treat; 2011 Jul; 128(1):85-95. PubMed ID: 20676758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIF-1α overexpression in ductal carcinoma in situ of the breast in BRCA1 and BRCA2 mutation carriers.
    van der Groep P; van Diest PJ; Smolders YH; Ausems MG; van der Luijt RB; Menko FH; Bart J; de Vries EG; van der Wall E
    PLoS One; 2013; 8(2):e56055. PubMed ID: 23409121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homologous repair of DNA damage and tumorigenesis: the BRCA connection.
    Jasin M
    Oncogene; 2002 Dec; 21(58):8981-93. PubMed ID: 12483514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
    Suh KJ; Ryu HS; Lee KH; Kim H; Min A; Kim TY; Yang Y; Lee HB; Moon HG; Han SW; Oh DY; Han W; Park IA; Noh DY; Im SA
    Breast Cancer Res Treat; 2019 May; 175(1):117-127. PubMed ID: 30671767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.